Novartis AG (NVS) Given Consensus Recommendation of “Hold” by Brokerages
Novartis AG (NYSE:NVS) has earned an average recommendation of “Hold” from the nineteen analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $81.59.
NVS has been the topic of a number of recent analyst reports. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday, September 5th. BidaskClub upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Cowen and Company reiterated a “hold” rating on shares of Novartis AG in a research note on Tuesday, July 18th. Zacks Investment Research lowered shares of Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Finally, Barclays PLC upgraded shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday, June 22nd.
A number of institutional investors have recently bought and sold shares of the business. Farr Miller & Washington LLC DC grew its position in Novartis AG by 0.3% in the second quarter. Farr Miller & Washington LLC DC now owns 2,959 shares of the company’s stock worth $247,000 after buying an additional 10 shares during the last quarter. FCG Advisors LLC grew its position in Novartis AG by 0.3% in the second quarter. FCG Advisors LLC now owns 4,271 shares of the company’s stock worth $357,000 after buying an additional 12 shares during the last quarter. Washington Trust Bank grew its position in Novartis AG by 0.3% in the second quarter. Washington Trust Bank now owns 4,384 shares of the company’s stock worth $366,000 after buying an additional 14 shares during the last quarter. North Star Investment Management Corp. grew its position in Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock worth $129,000 after buying an additional 16 shares during the last quarter. Finally, Ledyard National Bank grew its position in Novartis AG by 0.9% in the second quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock worth $286,000 after buying an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 10.92% of the company’s stock.
Novartis AG (NYSE NVS) traded down 0.46% during trading on Thursday, reaching $85.99. The company’s stock had a trading volume of 1,229,028 shares. The firm has a 50 day moving average of $85.07 and a 200 day moving average of $81.69. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90. The stock has a market capitalization of $201.47 billion, a price-to-earnings ratio of 31.39 and a beta of 0.73.
Novartis AG (NYSE:NVS) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion for the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 earnings per share. Analysts expect that Novartis AG will post $4.75 EPS for the current year.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.